Gene · 2348
Papers3,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 3,253
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exploring commutable materials for serum folate measurement: challenges in cross-method harmonization. | Clin Chem Lab Med | 2025 | 40560660 | PubTator, text mining | PubMed |
| Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models. | Mol Cancer Ther | 2025 | 40545684 | PubTator, text mining | PubMed |
| Quantitative and qualitative metrics of tumor stroma in predicting ovarian cancer outcomes and expansion of its study with AI-based tools. | Mol Ther Oncol | 2025 | 40524858 | PubTator, text mining | PubMed |
| Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment. | Oncogene | 2025 | 40514426 | PubTator, text mining | PubMed |
| The Antibody-Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma. | Mol Cancer Ther | 2025 | 40509933 | PubTator, text mining | PubMed |
| Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker. | Int J Mol Sci | 2025 | 40508029 | PubTator, text mining | PubMed |
| Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers. | Cancers (Basel) | 2025 | 40507303 | PubTator, text mining | PubMed |
| Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. | Future Oncol | 2025 | 40501444 | PubTator, text mining | PubMed |
| State of the Art: Therapies Now and Around the Corner for Gynecologic Cancers. | Am Soc Clin Oncol Educ Book | 2025 | 40489723 | PubTator, text mining | PubMed |
| Folate transfer in placental choriocarcinoma cells treated with valproic acid: Insights gained through comparisons with the amide derivative sec-butylpropylacetamide and its individual stereoisomers. | Epilepsia | 2025 | 40464080 | PubTator, text mining | PubMed |
| FOLR1-Targeted Oxygen-Delivering Nanosomes Enhance Chemo-Induced Apoptosis in Hypoxic Cancer. | Int J Nanomedicine | 2025 | 40458747 | PubTator, text mining | PubMed |
| A new approach to the treatment of ovarian cancer: The application of CAR-T cell therapy. | Crit Rev Oncol Hematol | 2025 | 40449673 | PubTator, text mining | PubMed |
| Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer. | Eur J Cancer | 2025 | 40446758 | PubTator, text mining | PubMed |
| Assessment of biophysical properties of the first-in-class anti-cancer IgE antibody drug MOv18 IgE demonstrates monomeric purity and stability. | MAbs | 2025 | 40432600 | PubTator, text mining | PubMed |
| UV-Cross-Linked DNA Nanomaterials Enable Robust Nanopatterning of Folate Ligands for Enhanced Cellular Uptake. | J Am Chem Soc | 2025 | 40402870 | PubTator, text mining | PubMed |
| The Role of Folate Receptor α Autoantibodies in Folate Deficiency, Disease Severity, and Treatment Response in Adolescents with Major Depressive Disorder. | J Nutr | 2025 | 40379028 | PubTator, text mining | PubMed |
| The clinical significance and potential therapeutic target of tumor-associated macrophage in non-small cell lung cancer. | Front Med (Lausanne) | 2025 | 40370720 | PubTator, text mining | PubMed |
| Nanotechnology in cancer treatment: revolutionizing strategies against drug resistance. | Front Bioeng Biotechnol | 2025 | 40370595 | PubTator, text mining | PubMed |
| FRα expression in advanced endometrial carcinoma: Clinicopathological, molecular, and prognosis correlates. | Gynecol Oncol | 2025 | 40344965 | PubTator, text mining | PubMed |
| Enhancing surgical precision in ovarian cancer with FRα-fluorescence-guided surgery. | Eur J Surg Oncol | 2025 | 40344696 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2348/papers?page=13